Abstract
Purpose Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers in a wide array of cancer types and can be classified into three Classes according to molecular characteristics. Consensus treatment strategies for Class 2 and 3 BRAF mutations have not yet been established.
Methods We performed a systematic review and meta-analysis of individual patient data to assess treatment outcomes with FDA-approved mitogen activated protein kinase pathway (MAPK) targeted therapy according to BRAF Class, cancer type and MAPK targeted therapy type. A search was conducted on literature from 2010-2021. Individual patient data was collected and analyzed from published reports of patients with cancer harboring Class 2 or 3 BRAF mutations and who received MAPK targeted therapy with available treatment response data. Co-primary outcomes were response rate (RR) and progression-free survival (PFS).
Results 18167 studies were screened, identifying 80 studies with 238 patients that met inclusion criteria. This included 167 patients with Class 2 and 71 patients with Class 3 BRAF mutations. Overall, 77 patients achieved a treatment response. In both univariate and multivariable analyses, RR and PFS were higher among patients with Class 2 compared to Class 3 mutations, findings that remain when analyses are restricted to patients with melanoma or lung primary cancers. MEK +/- BRAF inhibitors demonstrated greater clinical activity in Class 2 compared to Class 3 BRAF mutant tumors than BRAF or EGFR inhibitors.
Conclusions This meta-analysis suggests that MAPK targeted therapies have clinical activity in some Class 2 and 3 BRAF mutant cancers. BRAF Class may dictate responsiveness to current and emerging treatment strategies, particularly in metastatic melanoma and lung cancers. Together, this analysis provides clinical validation of predictions made based on a mutation classification system established in the preclinical literature. Further evaluation with prospective clinical trials is needed for this population.
Competing Interest Statement
BJ: Consulting or Advisory: Gritstone bio; Incyte; Taiho Oncology; Insmed Oncology. Research Funding: BristolMyers Squibb, Syntrix IDJ: Has received honoraria from Foundation Medicine, Creative Education Concepts, Dava Oncology, OncLive, Total Health, and American Lung Association, consulting fees from Guidepost, AstraZeneca, Bayer, Boehringer Ingelheim, BostonGene, Catalyst, Genentech, Novocure, Pfizer, Syros, and Xcovery, research support from Array, Genentech, Novartis, Pfizer, and Guardant Health, and travel support from Array and Pfizer. MG: Research Funding BristolMyers Squibb; Merck KGaA; Roche ES: Honoraria Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Merck Serono; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha. TY: Honoraria: Chugai Pharmaceutical, Merck Biopharma, Bayer Yakuhin, Ono Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, Research Funding paid to institution: Chugai Pharma, MSD, Daiichi Sankyo Company, Parexel International Inc., Ono Pharmaceutica, Taiho Pharmaceutical,. Amgen, Sanofi. DK: Honoraria Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda JRF: pediatric advisory Board for Astra Zeneca OG: Advisory boards for Amgen, Lilly, Merck, Astrazeneca. Consultant for Amgen and Lilly. All honoraria paid to institution JM: Personal fees from Roche, Astra Zeneca, Pierre Fabre, Takeda, BMS, MSD, Jiangsu Hengrui, Blueprint, Daiichi, Novartis, Amgen. Grants for the Institution from Roche, Astra Zeneca, Pierre Fabre, BMS. JAS: Honoraria Apexigen; Array BioPharma/Pfizer; BristolMyers Squibb; Iovance Biotherapeutics; Jazz Pharmaceuticals. Consulting or Advisory Role Apexigen; Array BioPharma/Pfizer; BristolMyers Squibb; Iovance Biotherapeutics; Jazz Pharmaceuticals. Research Funding BristolMyers Squibb (Inst). SK: Stock and Other Ownership Interests: MolecularMatch, Navire. Consulting or Advisory Role: Roche, Genentech, EMD Serono, Merck, Karyopharm Therapeutics, Amal Therapeutics, Navire Pharma, Symphogen, Holy Stone, Biocartis, Amgen, Novartis, Eli Lilly, Boehringer Ingelheim, Boston Biomedical, AstraZeneca/MedImmune, Bayer Health. Research Funding: Amgen (Inst), Sanofi (Inst), Biocartis (Inst), Guardant Health (Inst), Array BioPharma (Inst), Roche (Inst), EMD Serono (Inst), MedImmune (Inst), Novartis (Inst). VS: Consulting or Advisory Role Helsinn Therapeutics; Loxo; MedImmune; QED Therapeutics; RPharm. Research Funding Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst). Travel, Accommodations, Expenses Bayer; Helsinn Therapeutics; Novartis; PharmaMar. Other Relationship Medscape. MAD: supported by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the AIM at Melanoma Foundation, the NIH/NCI (1 P50 CA221703 02 and 1U54CA224070 03), the American Cancer Society and the Melanoma Research Alliance, Cancer Fighters of Houston, the Anne and John Mendelsohn Chair for Cancer Research, and philanthropic contributions to the 3 Melanoma Moon Shots Program of MD Anderson. MAD has been a consultant to Roche/Genentech, Array, Pfizer, Novartis, BMS, GSK, SanofiAventis, Vaccinex, Apexigen, Eisai, and ABM Therapeutics, and he has been the PI of research grants to MD Anderson by Roche/Genentech, GSK, SanofiAventis, Merck, Myriad, and Oncothyreon. AG: Employed by BioMed Valley Discoveries. RJS: Consulting or Advisory Role alkermes; Asana Biosciences; AstraZeneca; BristolMyers Squibb; Eisai; Iovance Biotherapeutics; Merck; Novartis; OncoSec; Pfizer; Replimune. Research Funding Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Viralytics (Inst). KTF: stock and Other Ownership Interests Apricity Therapeutics; Checkmate Pharmaceuticals; Clovis Oncology; FOGPharma; Monopteros Therapeutics; Oncoceutics; PIC Therapeutics; Shattuck Labs; Strata Oncology; Tvardi Therapeutics; Vibliome Therapeutics; Vivid Biosciences; X4 Pharma; xCures. Consulting or Advisory Role Adaptimmune; Aeglea Biotherapeutics; Amgen; Apricity Therapeutics; Asana Biosciences; Boston Biomedical; BristolMyers Squibb; Checkmate Pharmaceuticals; Clovis Oncology; Debiopharm Group; FOGPharma; Fount Therapeutics; Genentech; Lilly; Merck; Monopteros Therapeutics; Neon Therapeutics; Novartis; Oncoceutics; PIC Therapeutics; Pierre Fabre; Sanofi; Shattuck Labs; Strata Oncology; Takeda; Tolero Pharmaceuticals; Tvardi Therapeutics; Verastem; Vibliome Therapeutics; Vivid Biosciences; X4 Pharma; xCures. Research Funding Novartis; Sanofi. DBJ: serves on advisory boards for Array Biopharma, Bristol Myers Squibb, Catalyst, Jansen, Iovance, Incyte, Merck, Novartis, and Oncosec, and receives research funding from Bristol Myers Squibb and Incyte. DWS: Consulting or Advisory Role Agendia; AstraZeneca; Exact Sciences; GlaxoSmithKline; Merck; Novartis; Pfizer; Roche/Genentech. AS: Honoraria BristolMyers Squibb; Janssen Oncology. Consulting or Advisory Role Bristol Myers Squibb; Merck; Novartis; Oncorus Research Funding Alkermes; Array BioPharma; AstraZeneca/MedImmune; Bayer; BristolMyers Squibb; GlaxoSmithKline; Janssen Oncology; Merck; Northern Biologics; Novartis; Replimune; Roche; Surface Oncology; Symphogen Travel, Accommodations, Expenses Bayer; BristolMyers Squibb; Idera; Janssen Oncology; Merck; Roche. AANR: Advisory board (Pfizer); Immediate family member is an employee of Merck. MD, YW, CN, NJM, GR, JWB, AB, GZ: No disclosures to declare.
Funding Statement
MD and YW acknowledge support from Vanier Canada Graduate Scholarships. GZ and AANR acknowledges support from a Fonds de Recherche du Quebec Sante (FRQS) Clinical Research Scholar award. AANR is a recipient of a Conquer Cancer Foundation of ASCO Young Investigator Award
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
A literature search was conducted of studies published from January 2010 to September 2021 in the following databases: Medline ALL (Medline and Medline Epub Ahead of print and In-Process & Other Non-Indexed Citations), Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, all from the OvidSP platform, and Web of Science from Clarivate Analytics.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
